Results 131 to 140 of about 53,629 (166)

Bone Effects of Anti-Cancer Treatments in 2024. [PDF]

Calcif Tissue Int
Teissonnière M, Point M, Biver E, Hadji P, Bonnelye E, Ebeling PR, Kendler D, de Villiers T, Holzer G, Body JJ, Fuleihan GEH, Brandi ML, Rizzoli R, Confavreux CB.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis.

Current Drug Targets, 2017
Osteoporosis, a bone disease resulting in the loss of bone density and microstructure quality, is often associated with fragility fractures, and the latter imposes a great burden on the patient and society. Although there are several different treatments
Taoxue Wang, Qian Liu, William Tjhioe, Jinmin Zhao, Aiping Lu, Ge Zhang, R. Tan, Mengyu Zhou, Jiake Xu, H. Feng   +9 more
semanticscholar   +1 more source

MEDICATION-RELATED OSTEONECROSIS OF THE JAW: A REVIEW STUDY

Revista contemporânea
Osteonecrosis of the jaws, related to the use of medications, is a condition that can arise because of therapies with antiresorptive drugs, such as bisphosphonates and Denosumab, or with antiangiogenic agents. Although not very common, this condition can
Waléria Pinheiro de Araújo, Lara Oliveira de Jesus, Roberta Oliveira Volponi, Renan Rodrigues Silva, Kamylla Carvalho de Souza, Fernanda Ladim Cruz, Eduardo Lins de Araújo, Vilmar Santos de Almeida, Pedro dos Santos Anjo e Aguero, Sâmyla Amanda Rodrigues dos Santos, Larissa Pinheiro Silva, Antônia Camila Farias, Hellen Anny Ricarte Leite, Alane Raiane Soares Mendonça   +13 more
semanticscholar   +1 more source

A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression.

Thyroid, 1994
Thyroid hormone has been shown to stimulate bone resorption. Both endogenous hyperthyroidism and exogenous thyroxine suppressive therapy have been associated with reduction in bone mineral density (BMD), but the patholophysiology of thyroxine-induced ...
A. Kung, F. Ng
semanticscholar   +1 more source

Antidiabetic Agents and Bone Quality: A Focus on Glycation End Products and Incretin Pathway Modulations

Journal of Bone Metabolism
Diabetes mellitus is associated with inadequate bone health and quality and heightened susceptibility to fractures, even in patients with normal or elevated bone mineral density.
Muthanna K. Zaki, M. Abed, F. Alassaf
semanticscholar   +1 more source

Verifying the effectiveness of romosozumab re-administration on bone mineral density.

Journal of Bone and Mineral Research
Upon completing romosozumab therapy for osteoporosis, sequential treatment with other agents is required. However, for patients at high fracture risk despite such therapy, re-administration of romosozumab might be a potent option for subsequent ...
T. Kobayakawa, Yukio Nakamura
semanticscholar   +1 more source

Characterization of bone lesions and bone mineral density of roadkilled wild animals in the Brazilian semi-arid

Neotropical Biology and Conservation
Highways are one of the anthropogenic factors that have the greatest impact on terrestrial biodiversity. Barriers, depletion effects, and roads are the most common locations of wild animal roadkill, leading to biodiversity loss in wild vertebrates ...
Itainara Taili, Fabiano Séllos Costa, João Marcelo Azevedo de Paula Antunes, A. Shimabukuro, Raul dos Santos, Sofia de Oliveira Cabral, C. Calabuig   +6 more
semanticscholar   +1 more source

Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones

Journal of Bone and Joint Surgery. American volume
Background: Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications.
Neil P. Sheth, James Russell Smith, R. Winzenrieth, Ludovic Humbert, Yamei Wang, John I. Boxberger, Mathias P Bostrom   +6 more
semanticscholar   +1 more source

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Journal of Clinical Oncology, 2017
Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer.
S. Dhesy-Thind, G. Fletcher, P. Blanchette, M. Clemons, Melissa S. Dillmon, E. Frank, S. Gandhi, Rasna Gupta, M. Mates, B. Moy, T. Vandenberg, C. V. Van Poznak   +11 more
semanticscholar   +1 more source

Bone-modifying therapy in arthroplasty

Bone and soft tissue sarcomas, tumors of the skin
The use of bisphosphonates in medicine began in the 60s of the XX century due to their ability to prevent the dissolution of hydroxyapatite and thereby to reduce bone loss.
A. V. Bukharov, D. A. Erin, V. Derzhavin, A. V. Yadrina, D. O. Elkhov, M. D. Aliev, Z. K. Khuseynzoda   +6 more
semanticscholar   +1 more source